FrancophonIA/ELRC3.0 huggingface dataset:
English: Moxifloxacin should be used with caution in patients with any condition pre-disposing to cardiac arrhythmias (e.g. acute myocardial ischaemia) because they may have an increased risk of developing ventricular arrhythmias (incl.
Slovenian: Moksifloksacin je treba uporabljati previdno pri bolnikih s kakršnokoli predispozicijo za srčne aritmije (npr. akutna miokardna ishemija) ker se lahko poveča tveganje za pojav ventrikularne aritmije (vključno torsades de pointes) in srčnega zastoja.
English: Moxifloxacin undergoes Phase II biotransformation and is excreted via renal (approximately 40%) and biliary/faecal (approximately 60%) pathways as unchanged drug as well as in the form of a sulphocompound (M1) and a glucuronide (M2).
Slovenian: fazi, izloča pa se s sečem (približno 40 %) in žolčem/blatom (približno 60 %), in sicer kot nespremenjeno zdravilo, pa tudi v obliki žveplove spojine (M1) in glukuronida (M2).
English: The cumulative review of spontaneous ADR reports of serious “possible drug related hepatic disorders” on IV only or IV/oral sequential treatment, suggested that serious moxifloxacin-induced hepatic events were very rare, unpredictable and idiosyncratic and that the benefit-risk has not changed for IV moxifloxacin.
Slovenian: Kumulativni pregled poročil o spontanih neželenih učinkih, tj. resnih „možnih, z zdravili povezanih okvar jeter“ pri samo intravenoznem ali intravenoznem / peroralnem zaporednem zdravljenju, nakazuje, da so resni jetrni dogodki, povzročeni z moksifloksacinom, zelo redki, nepredvidljivi in idiosinkratični ter da se razmerje med koristmi in tveganji za intravenozno zdravljenje z moksifloksacinom ni spremenilo.
English: +Methicillin resistant S. aureus have a high probability of resistance to fluoroquinolones.
Slovenian: + Pri proti meticilinu odpornem S. aureus obstaja verjetnost, da je odporen tudi proti fluorokinolonom.
English: In dogs, high oral doses (≥ 60 mg/kg) leading to plasma concentrations ≥ 20 mg/l caused changes in the electroretinogram and in isolated cases an atrophy of the retina.
Slovenian: Pri psih, ki so dobivali velike peroralne odmerke (≥ 60 mg/kg), zaradi česar so bile plazemske koncentracije ≥ 20 mg/l, se je spremenil elektroretinogram, v posameznih primerih pa se je pojavila atrofija mrežnice.
English: An additive effect on QT interval between moxifloxacin and other medicinal products that may prolong the QTc interval cannot be excluded.
Slovenian: Pri sočasni uporabi moksifloksacina in drugih zdravil, ki lahko podaljšajo interval QTc, ne moremo izključiti aditivnega učinka na interval QT.
English: Spontaneous reporting rates are higher for IV/sequential treatment than for oral treatment and the Applicant's argument that this is accounted for by the greater background morbidity in the population treated with IV/PO compared to those treated only with PO moxifloxacin can be partly accepted.
Slovenian: Stopnja poročanih spontanih neželenih učinkov je za intravenozno/zaporedno zdravljenje višja kot za peroralno zdravljenje, predlagateljeva trditev, da je razlog za to večja osnovna obolevnost populacije, zdravljene intravenozno/peroralno, kot pri tistih, ki so jih zdravili z moksifloksacinom zdravili le peroralno, pa se lahko sprejme le delno.
English: The CHMP considers that the totality of the safety data relating to use of moxifloxacin (IV and oral and IV/PO) should be taken into account together when assessing the overall benefit-risk and therefore, the safety profile described for oral administration applies to intravenous administration, with the additional expectation that the difference in PK and in patient and infection characteristics for those in need of initial IV treatment is likely to increase any risks associated with systemic administration.
Slovenian: CHMP je menil, da je treba pri oceni splošnega razmerja med koristmi in tveganji upoštevati vse podatke o varnosti glede uporabe moksifloksacina (intravenozno, peroralno in intravenozno/peroralno), in da zato profil varnosti, opisan za peroralno uporabo, velja tudi za intravenozno uporabo, pri čemer se tudi pričakuje, da se bo pri bolnikih, ki potrebujejo začetno intravenozno zdravljenje, verjetno zaradi razlik v farmakokinetiki, v značilnostih bolnika in okužbe povečalo tveganje, povezano s sistemsko uporabo zdravila.
English: Dyspnea (including asthmatic conditions)
Slovenian: težave pri dihanju (tudi astma)
English: Refer to sections 4.3, 4.4 and 4.5.
Slovenian: Glejte poglavja 4.3, 4.4. in 4.5.
English: Headache Dizziness
Slovenian: vnetje ven
English: There have been very rare cases of the following side effects reported following treatment with other fluoroquinolones, which might possibly also occur during treatment with moxifloxacin: transient loss of vision, hypernatraemia, hypercalcaemia, haemolysis, rhabdomyolysis, photosensitivity reactions (see section
Slovenian: Med zdravljenjem z drugimi fluorokinoloni so poročali o zelo redkih primerih naslednjih neželenih učinkov, ki bi se prav tako lahko pojavili tudi med zdravljenjem z moksifloksacinom: prehodna izguba vida, hipernatriemija, hiperkalciemija, hemoliza, rabdomioliza, fotosenzitivne reakcije (glejte poglavje
English: Interaction with food Moxifloxacin has no clinically relevant interaction with food including dairy products.
Slovenian: Interakcije s hrano Pomembnejših interakcij moksifloksacina s hrano ni (vključno z mlečnimi izdelki).
English: On the grounds of safety and benefit-risk, the CHMP maintains its position that both indications for use of IV moxifloxacin should be qualified with the same wording as for the cSSSI indication.
Slovenian: Na podlagi varnosti in razmerja med koristmi in tveganji CHMP še naprej meni, da morata biti obe indikaciji za uporabo intravenoznega moksifloksacina opredeljeni z enakim besedilom kot indikacija za zapletene okužbe kože in mehkih tkiv.
English: Furthermore, there have been very rare cases of the following side effects reported following treatment with other quinolone antibiotics, which might possibly also occur during treatment with Octegra: transient loss of vision, increased blood sodium levels, increased blood calcium levels, increased breakdown of red blood cells, muscle reactions with muscle cell damage, increased sensitivity of the skin to sunlight or UV light.
Slovenian: V zelo redkih primerih so po zdravljenju z drugimi kinolonskimi antibiotiki poročali o naslednjih neželenih učinkih, ki se lahko prav tako pojavijo tudi med zdravljenjem z zdravilom Octegra: prehodna izguba vida, zvečane vrednosti natrija v krvi, zvečane vrednosti kalcija v krvi, povečan razpad eritrocitov, mišične spremembe s poškodbo mišičnih celic, povečana občutljivost kože za sončno ali UV svetlobo.
English: - Octegra may cause a rapid and severe inflammation of the liver which could lead to life-threatening liver failure (including fatal cases, see section 4.
Slovenian: Zdravilo Octegra lahko povzroči nenadno in hudo vnetje jeter, kar lahko povzroči življenjsko ogrožajočo jetrno odpoved (vključno s smrtnimi primeri) (glejte poglavje 4.
English: - If you suffer from myasthenia gravis using Octegra may worsen the symptoms of your disease.
Slovenian: Če imate miastenijo gravis, lahko jemanje zdravila Octegra poslabša znake vaše bolezni.
English: A total of 6 IV/PO studies in CAP were presented, however, the pooling of data across studies was considered inappropriate and overall, the data suggested that moxifloxacin may not be quite as good as a very good comparative regimen.
Slovenian: Predložili so skupno 6 študij intravenoznega/peroralnega zdravljenja izvenbolnišnično pridobljene pljučnice, vendar pa zbiranje podatkov v študijah ni bilo primerno, na splošno pa so podatki kazali, da moksifloksacin morda ni tako dobro zdravilo v primerjavi z zelo dobrim primerjalnim režimom zdravljenja.
English: Moxifloxacin has been shown to prolong the QTc interval on the electrocardiogram in some patients.
Slovenian: Moksifloksacin pri nekaterih bolnikih podaljša interval QTc na elektrokardiogramu.
English: double and blurred vision
Slovenian: motnje vida (tudi dvojni in zamegljen vid)
English: Liver Common:
Slovenian: Jetra Pogosti:
English: - Tendon inflammation and rupture may occur with quinolone therapy including moxifloxacin, particularly in elderly patients and in those treated concurrently with corticosteroids.
Slovenian: Med zdravljenjem s kinoloni, vključno z moksifloksacinom, se lahko pojavi vnetje in ruptura kit, predvsem pri starejših bolnikih in tistih, ki se sočasno zdravijo s kortikosteroidi.
English: Common ≥ 1/100 to < 1/10
Slovenian: organski sistem pogosti > 1/100 do < 1/10
English: administration is only slightly higher than that observed after oral administration (35 mg·h/l) in accordance with the absolute bioavailability of approximately 91%.
Slovenian: Vrednost AUC (približno 39 mg·h/l), dosežena po intravenski uporabi, je le malce višja od koncentracije, ki so jo opazili po peroralni uporabi (35 mg·h/l), kar je v skladu z absolutno biološko uporabnostjo, ki je približno 91 %.
English: No precaution is required for use with digoxin.
Slovenian: Ob sočasnem jemanju z digoksinom posebna previdnost ni potrebna.
English: There are no clinical data to demonstrate that moxifloxacin is active against pneumococci that are insusceptible to other fluoroquinolones as a result of acquired resistance.
Slovenian: Klinični podatki, ki bi dokazali delovanje moksifloksacina proti pnevmokokom, neobčutljivim na druge fluorokinolone kot rezultat pridobljene odpornosti, ne obstajajo.
English: See also sections 4.3 and 4.5.
Slovenian: Glejte tudi poglavje 4.3 in 4.5.
English: - The efficacy of Octegra in the treatment of severe burns, infections of deep tissue, major purulent ulcers (abscesses) and diabetic foot infections with osteomyelitis (infections of the bone marrow) has not been established.
Slovenian: Učinkovitost zdravila Octegra pri zdravljenju opeklin, okužb globokih tkiv, obsežnejših gnojnih razjed (abscesov) in okužb diabetične noge z osteomielitisom (okužba kostnega mozga) ni dokazana.
English: No TdPs were reported in over 15,000 patients in clinical studies and in over 90,000 patients in Post Marketing Studies and the frequency of treatment-emergent serious cardiac events was similar to that of the comparator.
Slovenian: V kliničnih študijah s preko 15 000 bolniki in študijah po začetku trženja s preko 90 000 bolniki niso zabeležili nobenega primera Torsade de Pointes, pojavnost resnih srčnih dogodkov, ki zahtevajo nujno zdravljenje, pa je bilo podobno kot pri primerjalnem zdravilu.
English: the CHMP has recommended the amendment of the Summary of Product Characteristics and the granting of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Octegra and associated names (see Annex I).
Slovenian: CHMP je priporočil dopolnitev povzetka glavnih značilnosti zdravila in odobritev dovoljenj za promet z zdravilom Octegra in z njim povezanimi imeni (glejte Dodatek I), katerih povzetek glavnih značilnosti zdravila, označevanje in navodila za uporabo so navedeni v Dodatku III.
English: For reasons of drug safety, moxifloxacin is therefore contraindicated in patients with: - Congenital or documented acquired QT prolongation - Electrolyte disturbances, particularly in uncorrected hypokalaemia - Clinically relevant bradycardia - Clinically relevant heart failure with reduced left-ventricular ejection fraction - Previous history of symptomatic arrhythmias
Slovenian: Zaradi varnostnih razlogov je uporaba moksifloksacina kontraindicirana pri bolnikih s/z: prirojenim ali dokazano pridobljenim podaljšanjem intervala QT, motnjami elektrolitskega ravnotežja, zlasti z nezdravljeno hipokaliemijo, klinično pomembno bradikardijo, klinično pomembnim srčnim popuščanjem in zmanjšano iztisno frakcijo levega prekata, simptomatskimi aritmijami v anamnezi.
English: After repeated dosing in healthy volunteers moxifloxacin increased Cmax of digoxin approximately 30% without affecting AUC or trough levels.
Slovenian: Po večkratnem odmerjanju moksifloksacina so se pri zdravih prostovoljcih največje koncentracije digoksina (Cmax) zvečale za približno 30 %, površina pod krivuljo (AUC) oz. najnižje vrednosti pa se niso spremenile.
English: Moxifloxacin resistance rate of > 50% have been reported for methicillin resistant S. aureus.
Slovenian: Pri proti meticilinu odpornem S. aureus so poročali o > 50 % stopnji odpornosti proti moksifloksacinu.
English: It was considered that the efficacy of moxifloxacin in the two indications claimed is adequate.
Slovenian: Ugotovljeno je bilo, da je učinkovitost moksifloksacina za dani indikaciji ustrezna.
English: Cross resistance should be expected between moxifloxacin and other fluoroquinolones.
Slovenian: Med moksifloksacinom in drugimi fluorokinoloni se lahko pričakuje navzkrižno odpornost.
English: If this happens treatment with Octegra solution for infusion has to be discontinued immediately.
Slovenian: Če se to pojavi, je treba takoj prenehati uporabljati raztopino za infundiranje Octegra.
English: For more details see below and refer to sections 4.3 and 4.5.
Slovenian: Za podrobnosti glejte spodnja opozorila in poglavji 4.3 in 4.5.
English: - the benefit-risk relationship for use of moxifloxacin to treat these infections was considered to be favourable only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections,
Slovenian: - razmerje med koristmi in tveganji ob uporabi moksifloksacina za zdravljenje teh okužb je ugodno le, ko uporaba protibakterijskih učinkovin, ki se navadno priporočajo za začetno zdravljenje teh okužb, ni primerna.
English: Moxifloxacin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.
Slovenian: Moksifloksacin se lahko uporablja le, ko uporaba protibakterijskih učinkovin, ki se navadno priporočajo za začetno zdravljenje teh okužb, ni primerna.
English: Octegra is packaged in cartons containing a 250ml glass bottle with a chlorobutyl rubber stopper.
Slovenian: Zdravilo Octegra je pakirano v škatle, ki vsebujejo 250 ml steklenice s klorobutilnim gumijastim zamaškom.
English: - There is a rare chance that you may experience a severe, sudden allergic reaction (an anaphylactic reaction/shock) even with the first dose, with symptoms that may include tightness in the chest, feeling dizzy, feeling sick or faint, or experience dizziness on standing.
Slovenian: Obstaja majhna verjetnost, da se že po prvi uporabi pojavi huda, nenadna alergijska reakcija (anafilaktična reakcija/šok) z znaki kot so tesnoba v prsnem košu, vrtoglavica, omedlevica ali omotica ob vstajanju.
English: In conclusion, the CHMP accepts that moxifloxacin may be indicated for the treatment of CAP, however the data it must be remembered that safety and benefit-risk were the main concerns triggering the referral and therefore, the conclusion that moxifloxacin has acceptable efficacy must be placed into context.
Slovenian: CHMP se naposled strinja, da je moksifloksacin lahko indiciran za zdravljenje izvenbolnišnično pridobljene pljučnice, vendar se ne sme pozabiti, da sta bila varnost in razmerje med koristmi in tveganji glavna zadržka, ki sta sprožila napotitveni postopek, zato je treba to upoštevati pri ugotovitvi, da je moksifloksacin sprejemljivo učinkovit,
English: The relationship between moxifloxacin concentrations and change in QTc interval was investigated in CAP and cSSSI studies and the Phase III trials suggested similar results for moxifloxacin and the comparators.
Slovenian: Razmerje med koncentracijami moksifloksacina in spremembami v intervalu QTc so raziskovali v študijah izvenbolnišnično pridobljene pljučnice in študijah zapletenih okužb kože in mehkih tkiv, študije 3. faze pa so nakazovale podobne rezultate za moksifloksacin in primerjalna zdravila.
English: Octegra should not be co-infused with other drugs.
Slovenian: Zdravilo Octegra ne smete infundirati hkrati z drugimi zdravili.
English: Note: This SPC, labelling and package leaflet is the version valid at the time of Commission Decision.
Slovenian: Opomba: Priložena verzija povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo je veljavna glede na odločbo komisije.
English: The Applicant discussed in depth the advantages of moxifloxacin for the treatment of CAP requiring initial IV therapy, providing data from clinical studies on the efficacy of moxifloxacin IV/oral, hepatic safety in sequential IV/oral and from studies on the cardiac safety in IV/oral.
Slovenian: Predlagatelj je obsežno razpravljal o prednostih moksifloksacina za zdravljenje izvenbolnišnično pridobljene pljučnice, kjer je potrebno začetno intravenozno zdravljenje, ob tem pa je predložil podatke iz kliničnih študij o učinkovitosti intravenoznega/peroralnega zdravljenja z moksifloksacinom, varnosti jeter pri zaporednem intravenoznem/peroralnem zdravljenju, in iz študij o varnosti srca pri intravenoznem/peroralnem zdravljenju.
English: The Applicant presented a summary of the monitoring of the susceptibility of relevant bacterial species to moxifloxacin through a systematic literature review.
Slovenian: Predlagatelj je na podlagi sistematskega pregleda gradiva predstavil povzetek nadzora občutljivosti pomembnih bakterijskih vrst na moksifloksacin.
English: In patients, there is no need for age or gender related dose adjustment on intravenous moxifloxacin.
Slovenian: Pri intravenski uporabi moksifloksacina bolnikom odmerkov ni treba prilagajati glede na starost ali spol.
English: increase of a special liver enzyme in the blood (LDH)), increase of bilirubin in the blood, increase of a special liver enzyme in the blood (gammaglutamyl-transferase and/or alkaline phosphatase)
Slovenian: jetrna okvara (tudi zvečane vrednosti posebnih jetrnih encimov v krvi (LDH)), zvečane vrednosti bilirubina v krvi, zvečane vrednosti posebnih jetrnih encimov v krvi (gamaglutamiltransferaze in/ali alkalne fosfataze)
English: General symptomatic therapy should be initiated.
Slovenian: Začeti je treba s splošnim simptomatskim zdravljenjem.
English: Moxifloxacin should be used with caution in patients who are taking medications associated with clinically significant bradycardia.
Slovenian: Moksifloksacin je treba uporabljati previdno pri bolnikih, ki jemljejo zdravila povezana z klinično pomembno bradikardijo.
English: If this becomes severe or persistent or you notice that your stool contains blood or mucus you should stop taking Octegra immediately and consult your doctor.
Slovenian: Če se pojavi huda in trdovratna driska ali če v blatu opazite kri ali sluz, se posvetujte s svojim zdravnikom, ker je treba takoj prenehati uporabljati zdravilo Octegra.
English: Uncommon: Tingling sensation (pins and needles) and/or numbness, changes in taste (in very rare cases loss of taste), confusion and disorientation, sleep problems (predominately sleeplessness), shaking, sensation of dizziness (spinning or falling over), sleepiness
Slovenian: občutek zbadanja (kot npr. z iglicami) in/ali odrevenelost, spremembe okušanja (v zelo redkih primerih izguba okusa), zmedenost in dezorientiranost, motnje spanja (pretežno nespečnost), tresenje, vrtoglavica, zaspanost
English: Finally, the Applicant claimed that the superior potency and pharmacokinetics of moxifloxacin avoids the selection of quinolone resistant isolates of
Slovenian: Na koncu je predlagatelj trdil, da se z večjo učinkovitostjo in farmakokinetiko moksifloksacina izognemo izbiri izolatov S. pneumnoiae, odpornih na kinolone.
English: 1 ml contains 1.6 mg moxifloxacin as hydrochloride.
Slovenian: 1 ml vsebuje 1,6 mg moksifloksacina v obliki moksifloksacinijevega klorida.
English: If you receive more Octegra than you should If you are concerned that you may have been received too much Octegra, contact your doctor immediately.
Slovenian: Če ste dobili večji odmerek zdravila Octegra, kot bi smeli Če menite, da ste dobili preveč zdravila Octegra, se takoj posvetujte z zdravnikom.
English: The frequencies of cardiac adverse events and adverse events were similar and the postmarketing observational studies and post-marketing surveillance of spontaneous adverse events do not show any evidence that IV/oral moxifloxacin is associated with a significantly higher risk of developing liver or cardiac adverse events than standard therapy.
Slovenian: Pogostost neželenih učinkov, povezanih s srcem, in neželenih učinkov na splošno je bila podobna, opazovalne študije po začetku trženja in nadzor spontanih neželenih učinkov po začetku trženja pa nikakor ne dokazujejo, da je intravenozno/peroralno zdravljenje z moksifloksacinom v primerjavi s standardnim zdravljenjem povezano z bistveno višjim tveganjem za nastanek neželenih učinkov, povezanih z jetri in srcem.
English: Swelling (of the hands, feet, ankles, lips, mouth, throat)
Slovenian: otekline rok, stopal, gležnjev, ustnic, ust in grla Mesto infundiranja
English: 250 ml pack available in cartons of 5 and 12 bags.
Slovenian: Vreče po 250 ml so na voljo v škatlah, ki vsebujejo 5 ali 12 vreč.
English: Therefore co-administration of moxifloxacin with any of the following medicinal products is contraindicated (see also section 4.3): - antiarrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide) - antiarrhythmics class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) - neuroleptics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride) - tricyclic antidepressive agents - certain antimicrobial agents (sparfloxacin, erythromycin IV, pentamidine, antimalarials particularly halofantrine) - certain antihistaminics (terfenadine, astemizole, mizolastine) - others (cisapride, vincamine IV, bepridil, diphemanil).
Slovenian: Sočasna uporaba moksifloksacina je zato kontraindicirana s katerimkoli od naslednjih zdravil (glejte tudi poglavje 4.3): antiaritmiki razreda IA (npr. kinidin, hidrokinidin, dizopiramid) antiaritmiki razreda III (npr. amiodaron, sotalol, dofetilid, ibutilid) nevroleptiki (npr. fenotiazini, pimozid, sertindol, haloperidol, sultoprid) triciklični antidepresivi nekatera protimikrobna zdravila (sparfloksacin, eritromicin IV, pentamidin, antimalariki, predvsem halofantrin) nekateri antihistaminiki (terfenadin, astemizol, mizolastin) drugi (cisaprid, vinkamin IV, bepridil, difemanil).
English: Therefore, do not take the following medicines during treatment with Octegra: Medicines that belong to the group of anti-arrhythmics (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide), neuroleptics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride), tricyclic antidepressants, some antimicrobials (e.g. sparfloxacin, intravenous erythromycin, pentamidine, antimalarials particularly halofantrine), some antihistamines (e.g. terfenadine, astemizole, mizolastine), and other medicines (e.g. cisapride, intravenous vincamine, bepridil and diphemanil).
Slovenian: Med zdravljenjem z zdravilom Octegra ne jemljite sočasno naslednja zdravila: zdravila, ki spadajo v skupino antiaritmikov (npr. kinidin, hidrokinidin, dizopiramid, amiodaron, sotalol, dofetilid, ibutilid), nevroleptike (npr. fenotiazini, pimozid, sertindol, haloperidol, sultoprid), triciklične antidepresive, nekatera protimikrobna zdravila (npr. sparfloksacin, intravenska oblika eritromicina, pentamidin, antimalariki, predvsem halofantrin), nekatere antihistaminike (npr. terfenadin, astemizol, mizolastin) in druga zdravila (npr. cisaprid, intravenska oblika vinkamina, bepridil, difemanil).
English: Increased blood sugar, increased blood uric acid Psychiatric Effects
Slovenian: zvečane vrednosti krvnega sladkorja, zvečane vrednosti sečne kisline v krvi Psihiatrične motnje
English: Contains sodium chloride, hydrochloric acid (for pH-adjustment), sodium hydroxide (for pH-adjustment) and water for injections.
Slovenian: Vsebuje natrijev klorid, klorovodikovo kislino (za uravnavanje pH), natrijev hidroksid (za uravnavanje pH) in vodo za injekcije.
English: When using Octegra - The risk of cardiac abnormalities may increase with the dose and the speed of the infusion into your vein.
Slovenian: Tveganje za srčne nepravilnosti se lahko poveča z odmerkom in hitrostjo infuzije v vašo veno.